At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
HB0017 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Placebo and HB0017 for Plaque Psoriasis. Completed, enrolled 160 participants across 21 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionMay 2023
Study CompletionJan 2024
TodayJul 2026
First PostedSep 8, 2022
Enrollment StartOct 25, 2022
Primary CompletionMay 23, 2023
Study CompletionJan 4, 2024
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 3.8 years ago
Interventions
Placeboother
Subjects will receive several injections of Placebo
HB0017drug
Subjects will receive HB0017 in different dosing regimens